Antamin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antamin

Antamin is a synthetic medicine defined by its core action as a potent first-generation antihistamine. Its function is to provide symptomatic relief by counteracting the effects of histamine, a substance integral to the body’s allergic response.


Property Description
Active ingredient Clemastine (as Clemastine Fumarate)
Form Tablet, Syrup, Solution for Injection
Pharmacological class First-Generation Antihistamine
General purpose Symptomatic relief of allergic reactions
Origin Synthetic, Ethanolamine derivative

What Type of Medicine is Antamin and What is its Core Purpose?

Antamin is a pharmaceutical preparation classified as a first-generation H1-receptor antagonist and a synthetic ethanolamine derivative. Its fundamental purpose is to provide symptomatic relief for acute body responses related to allergic reactions and hypersensitivity phenomena. The active ingredient, Clemastine Fumarate, works by blocking the actions of histamine, thereby reducing symptoms like generalized itching and swelling. Antihistamines in this class are used to inhibit the effects of histamine on capillary permeability and smooth muscle contraction, which supports their role in general symptom management.

The classification as a first-generation agent is noted for its ability to influence the central nervous system, contributing to a characteristic sedative effect alongside its primary antiallergic properties, a recognized feature of this class.

Composition and Available Pharmaceutical Forms

The core chemical entity in Antamin is Clemastine, supplied as the salt Clemastine Fumarate. This medicine is a single-ingredient product, its therapeutic activity derived entirely from the blockade of the H1 receptor. Clemastine Fumarate is formulated into multiple pharmaceutical presentations to suit varied patient needs and clinical settings. It is available for oral administration as a tablet, in liquid form as a syrup or oral solution, and as a sterile solution for injection, which allows for parenteral delivery for situations requiring rapid onset of action. This range of forms provides flexibility in administration routes based on the required speed and setting of the therapeutic intervention.

Regulatory References

  1. Clemastine: MedlinePlus Drug Information
  2. Antihistamines - StatPearls - NIH
  3. Clemastine - LiverTox - NIH
  4. CLEMASTINE FUMARATE syrup - DailyMed

What side effects are possible with Antamin?

Possible Side Effects and Safety Information

The safety profile of Antamin (Clemastine Fumarate) is primarily defined by effects on the Nervous System, alongside the potential for various systemic effects, as documented in official regulatory labeling from sources like the FDA and EMA. The information below reflects the adverse reactions and safety characteristics classified in these regulatory documents.


Frequency-Classified Adverse Reactions

The most characteristic effect is Somnolence (drowsiness or sedation), which is officially classified as Very Common. Other effects listed as Common in regulatory summaries include disturbance in attention, dizziness, headache, and dry mouth (Gastrointestinal Disorders). Rare events may include Hypersensitivity reactions, such as Anaphylactic shock.

Systemic and Serious Reactions

Adverse reactions are grouped by System-Organ Class (SOC) and can include effects on the Cardiovascular System (e.g., hypotension, tachycardia) and the Blood and Lymphatic System. The official safety documents list Serious adverse reactions such as Anaphylactic shock and rare Blood Dyscrasias (e.g., Agranulocytosis, Hemolytic anemia, Thrombocytopenia).

Population and Duration Notes

The risk profile requires specific consideration for certain populations. Older adults are documented as being more susceptible to certain side effects, including confusion, dizziness, and hypotension. In contrast, children may experience paradoxical excitement (restlessness or nervousness) rather than sedation. Official documents note that the risk of somnolence is typically highest during the initial days of treatment.

Safety-Related Restrictions

Due to the medicine's anticholinergic properties, caution is noted for use in individuals with conditions such as prostatic hypertrophy or bladder neck obstruction. Regulatory text also notes the potential for the medicine to cause a thickening of bronchial secretions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile documents that Antamin (Clemastine Fumarate) overdose may present with a complex range of central nervous system (CNS) effects. Overdose manifestations may include CNS depression, such as drowsiness and progression to coma, which is more common in adults. Conversely, CNS stimulation—including excitement, tremor, hallucinations, and convulsions—is particularly likely in children. Documented anticholinergic signs, such as hyperthermia, fixed, dilated pupils, and dry mouth, may also occur, alongside cardiovascular effects like hypotension and tachycardia.

Overdose is associated with severe outcomes, including cardiorespiratory arrest, cardiovascular collapse, and convulsions. Deaths are reported, especially in infants and children. Immediate medical help must be sought for any suspected overdose. Regulatory guidance mandates contacting emergency services if the individual has trouble breathing, has had a seizure, has collapsed, or cannot be awakened.

Management is strictly symptomatic and supportive, as official labeling states that no specific antidote or therapy is known for acute overdosage. Procedures may include gastric decontamination and specific treatment for severe effects, such as the use of a vasopressor for hypotension or appropriate agents to control convulsions.

Therapeutic Uses of Antamin

What Antamin Treats: Main Uses and Benefits

Antamin (Clemastine Fumarate) is applied across therapeutic domains where additional symptomatic support is needed, relevant in clinical settings that involve acute or disruptive symptom patterns. It is considered relevant in conditions presenting with significant symptomatic discomfort.

Antamin is used for easing symptoms of allergic rhinitis (hay fever) and urticaria (hives). It may assist with managing symptom clusters that may become intense or disruptive, such as sneezing, runny nose, watery eyes, and allergic itching. The medicine is applied across conditions characterized by periods of heightened symptoms.

Antamin’s primary benefit is in situations requiring short-term symptomatic assistance. It contributes to easing the overall symptom load during difficult episodes, offering supportive symptomatic relief when acute manifestations interfere with function. This medicine is also relevant for managing symptoms that interfere with daily comfort, supporting patients during episodes of heightened discomfort, especially when symptoms disrupt rest.

Quick Facts: Therapeutic Focus

  • Symptom Domains: Relevant for easing symptom clusters that may become intense, such as nasal/ocular discomfort and allergic itching.
  • Condition Categories: Commonly used across conditions characterized by periods of heightened symptoms, including hay fever and hives.
  • Patient Benefit: Supports general comfort during symptomatic periods and assists with maintaining functional stability.

Regulatory References

  1. US National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Antamin (chlorpheniramine) is an antihistamine primarily used to relieve symptoms associated with seasonal and perennial allergies, hay fever, and the common cold. Its use is generally considered appropriate for adults and children over a specific age threshold (usually 6 years old, though this may vary, and children under 2 years should generally avoid it unless directed by a physician), provided they do not have specific pre-existing health conditions.


Contraindications: Who Should Not Use Antamin

Antamin is contraindicated and should not be used by individuals with certain medical issues due to the risk of exacerbating the condition or causing serious side effects. Consult a healthcare professional immediately if any of these apply.

Contraindication Reason
Allergy/Hypersensitivity Known allergy to chlorpheniramine or any other ingredients in the product.
Lower Respiratory Disease Conditions like an acute asthma attack or active lower respiratory tract disease, as Antamin may thicken bronchial secretions.
Glaucoma Specifically narrow-angle glaucoma, due to the risk of increasing intraocular pressure.
Gastrointestinal/Urinary Obstruction Conditions such as a stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction (including symptomatic prostatic hypertrophy), as Antamin may worsen urinary retention or blockage.
Age Newborn or premature infants and generally children under 2 years of age. Older adults (65 and over) should use caution and lower doses due to increased sensitivity to side effects like drowsiness and confusion.

Special Populations: Pregnant and breastfeeding individuals should only use Antamin if clearly needed and the potential benefits outweigh the risks, as directed by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define clinically significant interactions for Antamin, necessitating specific restrictions or monitoring.

Contraindicated and High-Risk Combinations

Antamin is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including products like Eldepryl, Marplan, Nardil, or Parnate. Taking Antamin too soon after stopping an MAOI can lead to serious reactions; regulatory guidance mandates a 2-week washout period after discontinuing the MAOI before Antamin may be initiated.

Combinations Requiring Caution or Monitoring

Co-administration with alcohol and other Central Nervous System (CNS) depressants (such as opioids, sedatives, tranquilizers, or anti-anxiety agents) can result in additive CNS depression and should be avoided due to the increased risk of impaired mental alertness.

Antamin may also affect the metabolism of other medicines. Specifically, it can inhibit the hepatic metabolism of certain co-administered drugs like phenytoin, requiring monitoring of drug concentrations or adjustment to avoid potential toxicity.

Concurrent use with other anticholinergic drugs carries a risk of additive anticholinergic adverse effects. Furthermore, the effects and concentrations of Antamin may be altered by co-administered drugs that affect the Cytochrome P450 2D6 and 3A4 enzyme systems.

Mechanism of Action

Primary Mechanism: Histamine H1 Receptor Blockade

The core mechanism of Antamin (Clemastine) is its role as a competitive inverse agonist at the Histamine H1 receptor ( H1R). This highly specific interaction physically prevents endogenous histamine from binding to peripheral H1 receptors on blood vessel walls and sensory nerve endings. By stabilizing the H1R in an inactive state, the drug restricts the histamine-induced increase in capillary permeability and subsequent fluid leakage from the microvasculature.


Secondary Mechanism: Central and Autonomic Pathway Modulation

Clemastine's lipophilicity enables it to engage mechanisms outside the primary peripheral domain by crossing the blood-brain barrier. It modulates central pathways by blocking H1 receptors in the Central Nervous System, resulting in reduced arousal. The drug also acts as an antagonist at peripheral muscarinic acetylcholine receptors. This antimuscarinic action limits the stimulation of exocrine glands, which results in a reduction in certain physiological secretions.

Dosage and Administration Information

The administration of Antamin (chlorpheniramine maleate) must adhere strictly to the dosing and procedural guidelines.

Administration Scope

Feature Instruction
Route of Administration Oral for consumer products (tablets, syrups). Injection (IM, SC, or slow IV) for professional use.
Timing in Relation to Meals May be taken with or without food.
Frequency Pattern Immediate-release forms require dosing every 4 to 6 hours as needed. Extended-release forms are typically taken every 12 hours.

Official Dosing and Procedural Rules

Age Group Single Dose (4 mg tablet or equivalent) Maximum Daily Dose
Adults and Children ge 12 years 4 mg 24 mg (6 doses) in 24 hours
Children 6 to under 12 years 2 mg (half a scored 4 mg tablet) 12 mg (3 whole tablets equivalent) in 24 hours
Children under 6 years Not recommended for use with many single-ingredient oral products.

Special Procedural Conditions:

  • Extended-Release Forms must be swallowed whole; they should not be crushed, broken, or chewed.
  • Syrup/Oral Solution must be measured using an accurate milliliter measuring device, not a household spoon.
  • Missed Dose: If a regular dose is missed, take it when remembered, but if it is near the next scheduled dose, skip the missed dose. Do not take a double dose.
  • Elderly Patients (ge 65 years) should be considered for a lower maximum daily dose (e.g., 12 mg in 24 hours) due to increased sensitivity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antamin (Clemastine Fumarate)

Evidence for Use in Allergic Rhinitis (Hay Fever)

The research conducted has included short-term Randomized Controlled Trials (RCTs) and controlled experimental settings exploring Antamin's study in allergic rhinitis, commonly known as hay fever. These studies primarily focused on populations including adults and adolescents who experience seasonal or perennial allergic symptoms. The studies were conducted in contexts involving fluctuating or unstable symptoms, such as during periods of increased pollen exposure.

In these trials, research monitored outcomes related to specific physical discomforts often linked to allergies. Studies monitored patient-reported outcomes describing perceived discomfort related to sneezing frequency, the severity of a runny nose (rhinorrhea), and nasal or eye itching. The findings from these studies described patterns observed in the populations compared to control groups. This research contributes to understanding how patients reported their experience over short, defined time intervals.

While the evidence contributes to understanding symptom patterns, long-term outcomes and the evolution of symptom patterns following extended use are not well characterized by the existing body of short-term controlled trials. Data for certain groups, particularly concerning overall functional status, remain insufficient.


Evidence for Use in Urticaria and Allergic Skin Manifestations

Studies have explored Antamin in contexts assessing short-term or episodic symptom patterns, particularly for conditions associated with acute or disruptive episodes, such as urticaria (hives) and allergic itching. The core research base includes short-term RCTs that focused on individuals, including adults, adolescents, and children, presenting with these acute skin manifestations.

The primary study outcomes monitored changes in irritative states by examining the size and number of hives and changes in the subjective severity of itching. Trials focused on study outcomes related to symptom patterns shortly after administration, and studies report how symptoms evolved in the observed populations, with findings describing patterns observed in the relief of these allergic skin reactions. The evidence contributes to the broader evidence landscape related to medicines studied for symptomatic relief during acute episodes.

It is important to understand that existing studies are almost entirely focused on acute symptomatic management. Long-term effects are not fully established, and the research does not determine whether an individual will maintain similar symptom control over extended durations. The follow-up durations were typically limited.


What is Still Uncertain About the Research Landscape

Several areas remain uncertain or require further research to fully characterize Antamin's evidence base. Long-term effects are not fully established, and there is limited information on outcomes related to daily functioning or activity level over extended periods of time. The comparative evidence is lacking for systematically assessing Antamin against the newest generation of antihistamines regarding non-sedating efficacy profiles. The regulatory evidence base addresses study for acute symptomatic relief, but research is still ongoing to fully characterize every aspect of its use in complex, real-world conditions.

Key Studies & References

  1. Label: CLEMASTINE FUMARATE syrup - DailyMed - NIH (Indications and Regulatory Status)
  2. Label: CLEMASTINE FUMARATE tablet - DailyMed (Indications, Dosage Form Differences)

Frequently Asked Questions (FAQ)

Common questions about Antamin (FAQ)

Q: How quickly should I expect to feel the effects of Antamin?

According to official product information, the effects of Antamin generally begin to develop within 30 minutes after administration. The maximum effect is typically reached in about one to two hours after taking the tablet or syrup.


Q: Why do some people say Antamin makes their mouth dry?

Dry mouth is a common adverse reaction reported in regulatory documents. This effect is understood to be related to the drug's mechanism of action, specifically its anticholinergic properties, which can influence certain physiological secretions.


Q: Will Antamin interfere with birth control pills?

Official regulatory labels include a general caution that Antamin may affect the breakdown of other medicines in the liver, as it can influence the Cytochrome P450 enzyme systems. For patients taking oral contraceptives, professional guidance on monitoring may be necessary to address potential interactions.


Q: What is the shelf life of Antamin tablets?

Official storage guidelines instruct that the medicine must not be used after the expiry date printed on the packaging. The drug should be stored below 30 C and protected from light to maintain stability until that date. Referencing the product label is key for confirming the specific date.


Q: Is it better to take Antamin in the morning or evening?

Antamin can be taken with or without food. However, official information notes that the drug commonly causes somnolence (drowsiness), and this effect is often highest during the initial days of treatment. Considerations about the timing of the dose may be discussed with a healthcare provider in relation to daily activities and the potential for drowsiness.


Q: Why is Antamin sometimes used for sleep?

Antamin is a first-generation antihistamine, and regulatory documents classify somnolence (drowsiness) as a very common side effect. The drug works by crossing the blood-brain barrier, which affects the Central Nervous System to reduce arousal, a characteristic that accounts for its sedative effect.


Q: Does Antamin affect blood pressure?

Yes, official adverse reaction reports list potential effects on the cardiovascular system. These reactions include hypotension (low blood pressure) and tachycardia (fast heart rate).


Q: What type of patients is Antamin NOT recommended for?

The drug's official label states it is contraindicated, meaning it is not suitable for use, in patients with conditions such as an acute asthma attack, narrow-angle glaucoma, or certain obstructions like a stenosing peptic ulcer or bladder neck obstruction. It is also not suitable for newborn or premature infants.


Q: How long does Antamin typically stay in your system?

Based on pharmacokinetic studies, the plasma half-life of the active ingredient is estimated to be between 12 and 15 hours. This refers to the time it takes for half of the drug to be eliminated from the bloodstream.


Q: Do you need a prescription to get Antamin?

Antamin is available in some formulations as a HUMAN OTC DRUG (Over-The-Counter). However, regulatory status can vary based on the specific strength or formulation, with some forms requiring a prescription.


Q: Is Antamin safe for children over a certain age?

Dosing guidance is provided for children 6 to under 12 years old, but the use of many single-ingredient oral products is not generally recommended for children under 6 years. Official documents also note that children may experience paradoxical excitement (restlessness or nervousness) instead of drowsiness.


Q: Has Antamin been studied in pregnant women?

Official regulatory information states that there are no adequate data available from the use of the active ingredient in pregnant women. Regulatory guidance suggests the drug is only considered when the potential benefits clearly justify the potential risks.


Q: Is Antamin addictive in any way?

No. The FDA DailyMed label for the active ingredient indicates that it has No DEA Schedule assigned. This means it is not classified as a controlled substance under federal law.


Q: Can I take Antamin if I have kidney problems?

Regulatory documents include a caution for patients with severe renal impairment (significant kidney problems). Because the drug or its byproducts can accumulate, consideration of a lower initial dosage may be necessary.


Q: Will Antamin interfere with supplements like St. John's Wort?

Official regulatory warnings note that Antamin may interact with drugs that affect the liver's Cytochrome P450 enzyme systems. This includes many supplements. Disclosing all over-the-counter supplements and herbal products to a healthcare professional is considered important.


Q: What is the experience of long-term users of Antamin?

Existing research is primarily focused on acute symptomatic management using short-term controlled trials. Official documents note that long-term effects are not fully established, and the evidence regarding outcomes following extended use is limited.


Q: Can Antamin cause stomach upset or nausea?

Yes, official adverse reaction documents list nausea as a common reported reaction. Other gastrointestinal effects such as vomiting and abdominal pain have also been reported.


Q: Is there a liquid or chewable form of Antamin?

Antamin is available for oral administration in liquid form as a syrup or oral solution, as well as a tablet. Official documents do not specifically list a chewable form for the single-ingredient product.


Q: Is it possible to be allergic to Antamin itself?

Yes. Official information states that the drug is contraindicated for any individual with a known allergy or hypersensitivity to the active ingredient or any other component used in the product formulation.


Q: How should Antamin be stored?

Antamin should be stored at room temperature (below 30 C), away from heat, moisture, and direct light. The medicine must be kept safely out of the reach of children at all times.


Q: Is Antamin approved in countries outside the US?

Yes, the drug is documented and approved in other major jurisdictions, as evidenced by references to the EMA SmPC (European Medicines Agency) and MHRA Label (UK regulatory documents) in the official source information.


Q: Does Antamin have any known interaction with alcohol?

Yes. Co-administration of Antamin with alcohol is cautioned in official warnings. This combination can result in additive CNS depression, increasing the risk of severe drowsiness or sedation.


Q: Can Antamin be cut in half?

The ability to cut the pill depends on the specific product. The immediate-release tablet is typically scored for purposes such as preparing a lower dose for children. However, extended-release forms must always be swallowed whole and should never be crushed, broken, or chewed.


Q: Does Antamin interact with thyroid medication?

Official information includes a caution for use in patients with certain conditions like hyperthyroidism (overactive thyroid disease). This may necessitate monitoring of the patient's condition and overall regimen by a healthcare professional.


Q: Is Antamin safe for breastfeeding mothers?

For some product labels, use while breastfeeding is not recommended. Other regulatory guidance suggests that small, occasional doses may be considered. The use of Antamin requires evaluation by a healthcare professional, as non-sedating alternatives may be preferred.


Q: Is Antamin a Schedule IV controlled substance?

No. Official labeling indicates that the active ingredient is not assigned to any DEA Schedule. This means it is not classified as a controlled substance under federal law.


Q: Are there any black box warnings associated with Antamin?

Official documents show that some combination products that include Antamin's active ingredient have been documented with a Boxed Warning regarding risks. This warning primarily relates to the risks associated with other ingredients in the combination and specific use in children.

How should Antamin be stored and disposed of?

How to Store and Dispose of Antamin

Official regulatory documents define specific requirements for storing, handling, and disposing of Antamin (Chlorpheniramine Maleate) to maintain its stability and ensure safety.

Storage Requirement Official Instructions
Temperature and Environment Store below 30 C in a dry place.
Protection Protect from light.
Child Safety Keep out of the reach of children.
Shelf-Life Do not use this medicine after the expiry date.

The official disposal profile strictly prohibits discarding this medicine via wastewater (e.g., flushing) or general household waste. To ensure environmentally responsible disposal, patients are instructed to ask a pharmacist for guidance on how to properly discard any unused or expired Antamin.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antamin found in:

A-Z Index: